Ultrasonic-treated fucoidan as a promising therapeutic agent

Suprunchuk, V.E.

doi:10.17219/pim/143961

Cited by 6 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The OTUs were clustered with a cutoff value of 97% similarity using UPARSE (version 7.0.1001), and chimeric sequences were removed using UCHIME. The community composition analysis was performed and classified using the RDP classifier ( ) based on the SILVA ribosomal RNA gene database [ 77 , 78 , 79 ].…”

Section: Methodsmentioning

confidence: 99%

Fuc-S—A New Ultrasonic Degraded Sulfated α-l-Fucooligosaccharide—Alleviates DSS-Inflicted Colitis through Reshaping Gut Microbiota and Modulating Host–Microbe Tryptophan Metabolism

et al. 2022

View full text Add to dashboard Cite

Scope: The dysbiosis of intestinal microecology plays an important pathogenic role in the development of inflammatory bowel disease. Methods and Results: A polysaccharide named Fuc-S, with a molecular weight of 156 kDa, was prepared by the ultrasonic degradation of fucoidan. Monosaccharide composition, FTIR, methylation, and NMR spectral analysis indicated that Fuc-S may have a backbone consisting of →3)-α-L-Fucp-(1→, →4)-α-L-Fucp-(1→ and →3, 4)-α-D-Glcp-(1→. Moreover, male C57BL/6 mice were fed three cycles of 1.8% dextran sulfate sodium (DSS) for 5 days and then water for 7 days to induce colitis. The longitudinal microbiome alterations were evaluated using 16S amplicon sequencing. In vivo assays showed that Fuc-S significantly improved clinical manifestations, colon shortening, colon injury, and colonic inflammatory cell infiltration associated with DSS-induced chronic colitis in mice. Further studies revealed that these beneficial effects were associated with the inhibition of Akt, p-38, ERK, and JNK phosphorylation in the colon tissues, regulating the structure and abundance of the gut microbiota, and modulating the host–microbe tryptophan metabolism of the mice with chronic colitis. Conclusion: Our data confirmed the presence of glucose in the backbone of fucoidan and provided useful information that Fuc-S can be applied as an effective functional food and pharmaceutical candidate for IBD treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Fuc-S—A New Ultrasonic Degraded Sulfated α-l-Fucooligosaccharide—Alleviates DSS-Inflicted Colitis through Reshaping Gut Microbiota and Modulating Host–Microbe Tryptophan Metabolism

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The utilization of harsh extraction conditions such as acids, high temperatures, and long processing times should be avoided. Recently, novel delicate, eco-friendly processing technologies have been rapidly emerging, such as pressurized liquid extraction [ 121 ], ultrasound [ 122 ], microwave-assisted extraction [ 123 ], and biotechnology-mediated synthesis [ 124 , 125 , 126 , 127 ]. For instance, ultrasound-assisted extraction technique can positively affect the phytochemical composition of fucoidan (total fucoidan content and fucose/sulfate ratio) and it also accelerates the separation of the pharmacologically active compounds from the crude material, and hence, the anti-coagulant activity of fucoidan was improved after its topical administration to male Wistar rats [ 128 ].…”

Section: Scaling Up Production Of Fucoidan-based Formulations: Possib...mentioning

confidence: 99%

Fucoidan in Pharmaceutical Formulations: A Comprehensive Review for Smart Drug Delivery Systems

et al. 2023

View full text Add to dashboard Cite

Fucoidan is a heterogeneous group of polysaccharides isolated from marine organisms, including brown algae and marine invertebrates. The physicochemical characteristics and potential bioactivities of fucoidan have attracted substantial interest in pharmaceutical industries in the past few decades. These polysaccharides are characterized by possessing sulfate ester groups that impart negatively charged surfaces, low/high molecular weight, and water solubility. In addition, various promising bioactivities have been reported, such as antitumor, immunomodulatory, and antiviral effects. Hence, the formulation of fucoidan has been investigated in the past few years in diverse pharmaceutical dosage forms to be able to reach their site of action effectively. Moreover, they can act as carriers for various drugs in value-added drug delivery systems. The current work highlights the attractive biopharmaceutical properties of fucoidan being formulated in oral, inhalable, topical, injectable, and other advanced formulations treating life-quality-affecting diseases. Therefore, the present work points out the current status of fucoidan pharmaceutical formulations for future research transferring their application from in vitro and in vivo studies to clinical application and market availability.

show abstract

“…The application of ultrasonic destruction for decrease in the size of fucoidan molecules could expand the opportunities and spheres of their therapeutic application [4] .…”

Section: Modified Polysaccharides Under Ultrasound Irradiationmentioning

confidence: 99%

“…For one review paper published in 2015, the author discussed the potential effect of ultrasound on carbohydrates, especially the glycosylation of oligosaccharides, thioglycoside syntheses, and azidoglycoside syntheses [2] . The molecular mass of the polymer can be changed by means of various methods of depolymerisation, including ultrasonication, microwave, subcritical and enzyme degradation [3] , [4] . In addition, polysaccharides underwent physiochemical and functional changes during preparation, such as ultrasound, microwave and hydrothermal process [5] .…”

Section: Introductionmentioning

confidence: 99%

Critical review on alterations in physiochemical properties and molecular structure of natural polysaccharides upon ultrasonication

Jeepipalli

2022

Ultrasonics Sonochemistry

View full text Add to dashboard Cite

Ultrasonic-treated fucoidan as a promising therapeutic agent

Abstract: Suprunchuk V. Ultrasonic-treated fucoidan as a promising therapeutic agent [published online as ahead of print on December 15, 2021].

Cited by 6 publications

References 52 publications

Fuc-S—A New Ultrasonic Degraded Sulfated α-l-Fucooligosaccharide—Alleviates DSS-Inflicted Colitis through Reshaping Gut Microbiota and Modulating Host–Microbe Tryptophan Metabolism

Fuc-S—A New Ultrasonic Degraded Sulfated α-l-Fucooligosaccharide—Alleviates DSS-Inflicted Colitis through Reshaping Gut Microbiota and Modulating Host–Microbe Tryptophan Metabolism

Fucoidan in Pharmaceutical Formulations: A Comprehensive Review for Smart Drug Delivery Systems

Critical review on alterations in physiochemical properties and molecular structure of natural polysaccharides upon ultrasonication

Contact Info

Product

Resources

About